The 7 linked references in paper A. Tolkushin G., N. Pogudina L., А. Толкушин Г., Н. Погудина Л. (2018) “Фармакоэкономический анализ применения лекарственного препарата белимумаб на фоне стандартной терапии системной красной волчанки // Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus” / spz:neicon:pharmacoeconomics:y:2018:i:3:p:23-37

  1. Bruce I. N., O’Keeffe A. G., Farewell V. et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2015 Sep; 74 (9): 1706-13. DOI: 10.1136/annrheumdis-2013-205171.
  2. Bruce I. N., Urowitz M., van Vollenhoven R., Aranow C. et al. Long-term organ damage accrual and safety in patients with SLe treated with belimumab plus standard of care. Lupus. 2016 Jun; 25 (7): 699-709. DOI: 10.1177/0961203315625119.
  3. Jönsen A., Hjalte F., Willim M., Carlsson K. S. et al. Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts. Semin Arthritis Rheum. 2016 Jun; 45 (6): 684-90. DOI: 10.1016/j. semarthrit.2015.11.013.
  4. Aseeva e. A., Solov’ev S. K., Klyukvina N. G., Popkova T. V. et al. Nauchno-prakticheskaya revmatologiya. 2016; 54 (4): 404-411. https://doi.org/10.14412/1995-4484-2016-404-411.
  5. Manzi S., Sanchez-Guerrero J., Merrill J. T. et al. effects of belimumab, a B lymphocyte stimulator-specigic inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012; 71: 1833-1838. DOI: 10.1136/annrheumdis-2011-200831.
  6. Vollenhoven R. F., Petri M. A., Cervera R., Roth D. A., Ji B. N., Kleoudis C. S., Zhong Z. J., Freimuth W. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012 Aug; 71 (8): 1343-9. DOI: 10.1136/annrheumdis-2011-200937.
  7. Aseeva e.A., Soloviev S.K., Mesnyankina A.A., Reshetnyak T.M., Lopatina N.e., Glukhova S.I., Nasonov e.L. Results of an observational prospective study of the efficacy and safety of belimumab (Benlysta®) in systemic lupus erythematosus in real clinical practice. Rheumatology Science and Practice. 2016; 54 (1): 31-37. (In Russian). https://doi. org/10.14412/1995-4484-2016-31-37. [electronic resource] URL: https://rsp.imaress.net/rsp/article/view/2166. Accessed: 01.03.2018. (the paper at Socionet)